Liquidia: Sales are over-anticipated and pulmonary treatments have increased significantly

Liquidia, in a newspaper published on Wednesday, sold more than Wall Street expected in the second quarter, and the pulmonary treatment drug Yutrepia grew by double-digit sales. The company was prominent in its competition with United Therapeutics。